At a glance
ClinicalIndex Comparison RecordPhase 2Active· 32 enrolled
Drug / intervention
Tarlatamabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
In Brief
A Phase 2 clinical trial evaluating Tarlatamab for Extensive Stage Small Cell Lung Cancer. Active but no longer recruiting, targeting 32 participants across 12 sites.
Detailed Summary
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Active
202520262027
First PostedJul 2024
Enrollment StartAug 2024
Primary CompletionMar 2025
TodayJul 2026
Study CompletionJan 2027
First PostedJul 16, 2024
Enrollment StartAug 27, 2024
Primary CompletionMar 28, 2025
Study CompletionJan 8, 2027
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.0 years ago
Interventions
Tarlatamabdrug
IV infusion